SDAI LIMITED — Capital/Financing Update 2025

Aug 12, 2025

==> picture [91 x 91] intentionally omitted <==

SDAI Limited (Company Registration No. 201107179D)

(Incorporated in the Republic of Singapore on 25 March 2011)

FOR IMMEDIATE RELEASE

SDAI enters into a Strategic Cooperation Agreement with LiveBeyond to Jointly Pursue R&D in Anti-Aging Industry

• LiveBeyond is backed by a team of more than ten internationally recongised longevity professors with strong research capabilities specialising in the biology of aging and longevity, empowering individuals and organisations through access to advanced longevity research and medical solutions.

• The LiveBeyond research team is led by Professor Brian Kennedy, a globally renowned expert in the biology of aging. He currently serves as a Distinguished Professor in the Departments of Biochemistry and Physiology, and as the Director of the Healthy Longevity Translational Research Programme at the National University of Singapore.

• SDAI remains committed to growing the Company’s presence in the anti-aging sector and to delivering long-term value to shareholders of the Company.

SINGAPORE, 12 August 2025 – The board of directors (the “ Board ”) of SDAI Limited (the “ Company ” or “ SDAI ”, and together with its subsidiaries, the “ Group ”) is pleased to announce that the Company has, on 11 August 2025, entered into a strategic cooperation agreement with LiveBeyond Pte. Ltd. (“ LiveBeyond ”) to jointly pursue research, development and application initiatives in the field of anti-aging (“ Strategic Cooperation Agreement ”).

The Group and LiveBeyond agree, inter alia , to establish a joint venture (“ Joint Venture ”) in Hainan, China, and to collaborate through research and development related to anti-aging products and healthcare services. The Joint Venture and other initatives are subject to further deliberation between the parties and the details will be announced once finalised. The Strategic Cooperation Agreement is intended to build mutual understanding and support technical evaluation between the Group and LiveBeyond. Building on this foundation, both the Group and LiveBeyond plan to deepen their collaboration in anti-aging biotechnologies including, inter alia , stem cells, genetic engineering, exosomes and bio-based materials and focus on sectors such as medical treatments, healthcare and skincare.

SDAI Limited (Company Registration No. 201107179D)

==> picture [91 x 91] intentionally omitted <==

(Incorporated in the Republic of Singapore on 25 March 2011)

China's anti-aging market is experiencing robust growth, with its size projected to increase from US$544.8 million in 2024 to US$1.076 billion by 2035[1] . This expansion is driven by a rapidly aging population, supportive government policies and rising consumer spending on anti-aging products and services. These factors underscore the industry’s strong outlook and present a timely opportunity for the Group to capitalise on this emerging trend.

LiveBeyond specialises in delivering a comprehensive range of services that empower individuals and organisations by providing access to cutting-edge longevity research and medical solutions. Leveraging its strong research capabilities in the anti-aging industry, LiveBeyond collaborates with global partners to translate emerging innovations such as biological age diagnostics, healthspan biomarkers, regenerative medicine and age-related therapeutics into credible and scalable solutions. Its distinguished network of partners can be found in LiveBeyond’s website at the URL: https://www.livebeyond.ai.

LiveBeyond is backed by leading experts, including Professor Brian Kennedy[2] , who currently serves as a board member of LiveBeyond, He is presently a Distinguished Professor in the Departments of Biochemistry and Physiology as well as the Director of the Healthy Longevity Translational Research Programme in National University of Singapore and Director of the Centre for Healthy Longevity National University Health System. He is globally renowned for his contributions in the biology of aging and as a visionary committed to translating research discoveries into new ways to delay, detect and prevent human aging and its associated diseases. He leads groundbreaking longevity research programs focused on extending human lifespan and healthspan[2] . In addition, LiveBeyond is supported by a team of over ten internationally recognised longevity experts, each with decades of experience in the biology of aging.

Shareholders should note that information relating to LiveBeyond in the above two paragraphs and elsewhere in this announcement have been provided by LiveBeyond. The Company and the Directors have not independently verified the accuracy and correctness of such information herein.

Madam Hao Dongting (郝东亭), Executive Chairperson of the Board , said, “SDAI aims to expedite the Group’s transformation towards the biotechnology industry by collaborating with Professor Brian Kennedy and his professional team, who are distinguished professors in the field of aging science. We believe extensive expertise

1 - China Anti-Aging Services Market Overview, https://www.marketresearchfuture.com/reports/china anti-aging-services-market-50301,

2 - Profile of Professor Brian Kennedy, https://medicine.nus.edu.sg/bch/faculty/brian kennedy/

==> picture [91 x 91] intentionally omitted <==

SDAI Limited (Company Registration No. 201107179D) (Incorporated in the Republic of Singapore on 25 March 2011)

and insights from Professor Brian Kennedy and LiveBeyond can help us identify gaps in the current anti-aging industry and drive innovation in developing products that meet evolving consumer demands. This collaboration also presents an invaluable opportunity for our team to exchange knowledge and technical know-how. Moving ahead, we remain committed to growing our presence in the anti-aging sector and to delivering long-term value to our shareholders.”

• END -

About SDAI Limited

Listed on the Catalist Board of the Singapore Exchange since July 2011, SDAI Limited (" SDAI ", and together with its subsidiaries, the " Group ") is undergoing a strategic transformation into a biotechnology company specialising in healthcare-related products and services.

The Group plans to integrate biotechnology across the medical, skincare, and health products industries, and is committed to becoming a leading force in the biotechnology space.

For more information, please visit www.sdai.com.sg

_______________ Issued for and on behalf of SDAI Limited by Woodnote Consulting

Yong Jing Wen E: jingwen@woodnoteconsulting.com T: (65) 9860 3047

This press release has been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the " Sponsor ").

This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (the " SGX-ST ") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Yang Zhenni, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.